SOURCE: Cardima, Inc.

November 30, 2007 08:30 ET

Cardima Announces Departure of Dr. Arjun Sharma

FREMONT, CA--(Marketwire - November 30, 2007) - Cardima, Inc. (OTCBB: CADM), developer of the REVELATION® Tx, REVELATION® T-Flex ablation microcatheters and INTELLITEMP® Energy Management Device, announces today the departure of its Chief Medical Officer, Dr. Arjun Sharma, effective November 30, 2007 due to his acceptance of a senior position with a major medical device manufacturer.

We would like to thank Dr. Sharma for his contribution to the Company. Through the years, Dr. Sharma has worked extensively with Cardima on developing our ablation catheter technology and providing guidance on our clinical and regulatory affairs.

Commenting on his departure, Dr. Sharma said, "I have always been strong advocate for Cardima's products and I am very proud of my association with the Company. It has been an honor working with the talented staff and I wish the Company every success in the future."

On behalf of the Board of Directors and all the staff at Cardima, we would like to wish Dr. Sharma and his family well as he takes up his new role.

About Cardima

Cardima, Inc. has developed the PATHFINDER® Series of diagnostic catheters, the REVELATION® Series of ablation catheters, the INTELLITEMP® Energy Management Device, and the Surgical Ablation System (SAS). All of these devices are CE marked and received U.S. FDA 510(k) clearance. The REVELATION® Series with the INTELLITEMP® EP Energy Management Device was developed for the treatment of atrial fibrillation (AF) and received CE mark approval in Europe, however, is not currently available in the U.S.

For more information, please visit the Company's website at

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by such forward-looking statements. Potential risks and uncertainties include: the uncertainties associated with the prospects for FDA approval of any new devices; the prospect for any future clinical trials or regulatory activities; the risk that the Company will not be able to raise additional capital in the immediate term as needed to continue operations and the risk that we will be unable to secure a strategic transaction involving the Surgical Ablation System. Additional risks and uncertainties are set forth in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006, the Company's Quarterly Report on Form 10-QSB for the third quarter ended September 30, 2007, and in the Company's subsequent SEC filings. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.

Contact Information